Tango Therapeutics (TNGX) Shares Outstanding (2020 - 2026)
Tango Therapeutics (TNGX) posted quarterly Shares Outstanding (Entity) of $144.2 million for Q1 2026, up 33.35% year-over-year from $108.1 million in Q1 2025, and up 6.05% quarter-over-quarter from $135.9 million in Q4 2025.
Tango Therapeutics (TNGX) Shares Outstanding (2020 - 2026) Analysis & Trends
Tango Therapeutics' Shares Outstanding (Entity) history runs 7 years deep, the most recent figure standing at $144.2 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 33.35% year-over-year to $144.2 million; the TTM figure through Mar 2026 stood at $144.2 million (up 33.35% YoY), while the FY2025 annual figure was $135.9 million, up 26.19% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $144.2 million, up from $135.9 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $144.2 million in Q1 2026, with the low at $87.7 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $106.7 million (2024), against an average of $104.2 million.
- The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Entity) jumped 427.72% in 2022, then gained 0.53% in 2023.
- Tango Therapeutics' Shares Outstanding (Entity) stood at $88.2 million in 2022, then gained by 15.9% to $102.2 million in 2023, then gained by 5.41% to $107.7 million in 2024, then increased by 26.19% to $135.9 million in 2025, then climbed by 6.05% to $144.2 million in 2026.
- Business Quant data shows TNGX's Shares Outstanding (Entity) at $144.2 million in Q1 2026, $135.9 million in Q4 2025, and $111.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Tango Therapeutics | 4.32 Bn | 3.30 Bn | - | 149.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 149.88 Mn |
| Mar 31, 2026 | 143.58 Mn |
| Dec 31, 2025 | 116.17 Mn |
| Sep 30, 2025 | 110.97 Mn |
| Jun 30, 2025 | 110.54 Mn |
| Mar 31, 2025 | 110.30 Mn |
| Dec 31, 2024 | 109.23 Mn |
| Sep 30, 2024 | 108.51 Mn |
| Jun 30, 2024 | 108.31 Mn |
| Mar 31, 2024 | 108.17 Mn |
| Dec 31, 2023 | 94.57 Mn |
| Sep 30, 2023 | 97.03 Mn |
| Jun 30, 2023 | 88.35 Mn |
| Mar 31, 2023 | 88.19 Mn |
| Dec 31, 2022 | 87.82 Mn |
| Sep 30, 2022 | 87.89 Mn |
| Jun 30, 2022 | 87.84 Mn |
| Mar 31, 2022 | 87.67 Mn |
| Dec 31, 2021 | 62.11 Mn |
| Sep 30, 2021 | 70.16 Mn |